Objective: To investigate the clinical value of FT4, TSH, glycosylated hemoglobin and IGF-1 in evaluating the long-term treatment of children with short stature by recombinant human growth hormone. Methods: A total of short stature children treated in our hospital from December 2018 to January 2020 were selected as the observation group, and then 50 children were selected for health care in our hospital during the same period. Physical examination children were taken as control group, and free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), glycosylated hemoglobin (HbA1c) and insulin-like growth factor-1 were detected and compared between the two groups. (IGF-1) FT4, TSH, HbA1c and IGF-1 levels. The growth and development (height, body mass, bone age, growth rate), HbA1c, IGF-1 and insulin-like growth factor-binding protein-3 (IGFBP3) levels of the observation group were compared before treatment and after 3, 6, 12, and 24 months of treatment thyroid function indexes (FT3, FT4, TSH), bone metabolism and bone resorption indexes [alkaline phosphatase (AKP), collagen carboxy-terminal peptide isomer (CTX), osteocalcin (OC)] levels. Results: There was no significant difference in the levels of FT3, FT4, TSH and HbA1c between the two groups (P＞0.05). The IGF-1 level in the observation group was lower than that in the control group (P＜0.05). Compared with before treatment, the height, body mass, and bone age growth rate of observation group were higher after 3, 6, 12, and 24 months of treatment, and the differences were statistically significant (P＜0.05). The difference in growth rate between groups was statistically significant (P＜0.05), and all showed an increasing trend. Compared with before treatment, there was no significant difference in HbA1c levels in the observation group at 3, 6, 12, and 24 months after treatment (P＞0.05), and there was no significant difference between groups at different times (P＞0.05). Compared with before, the levels of IGF-1 and IGFBP3 were higher at 3, 6, 12, and 24 months after treatment (P＜0.05), and there were significant differences between groups at different times (P＜0.05). Compared with before treatment, there was no significant difference in the levels of FT3, FT4 and TSH in the observation group after 3, 6, 12, and 24 months of treatment (P＞0.05), and there was no difference in the levels of FT3, FT4 and TSH between groups at different times. Statistical significance (P＞0.05). Compared with before treatment, the levels of AKP, CTX and OC in the observation group were significantly increased after 3, 6, 12, and 24 months of treatment (P＜0.05). Conclusion: The long-term treatment of children with short stature with recombinant human growth hormone has no obvious adverse effects on the thyroid function and glucose metabolism of the children, and the growth and development of the children are significantly improved. Continuous detection of IGF-1, IGFBP3, bone metabolism and absorption levels can be achieved. Learn about treatment effects.